Last reviewed · How we verify
Dexamethasone, tobramycin, netilimicin
This is a combination of a corticosteroid (dexamethasone) and two aminoglycoside antibiotics (tobramycin and netilimicin) that reduces inflammation and provides broad-spectrum bacterial coverage.
This is a combination of a corticosteroid (dexamethasone) and two aminoglycoside antibiotics (tobramycin and netilimicin) that reduces inflammation and provides broad-spectrum bacterial coverage. Used for Bacterial infections with concurrent inflammation (likely ophthalmic or otic use).
At a glance
| Generic name | Dexamethasone, tobramycin, netilimicin |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Drug class | Corticosteroid + aminoglycoside antibiotics |
| Target | Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin, netilimicin) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Otolaryngology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone suppresses inflammatory and immune responses by binding glucocorticoid receptors, while tobramycin and netilimicin are aminoglycoside antibiotics that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. This combination is typically used topically or in localized settings to address both infection and inflammation simultaneously.
Approved indications
- Bacterial infections with concurrent inflammation (likely ophthalmic or otic use)
Common side effects
- Local irritation or burning
- Allergic reaction
- Ototoxicity (with systemic absorption)
- Nephrotoxicity (with systemic absorption)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone, tobramycin, netilimicin CI brief — competitive landscape report
- Dexamethasone, tobramycin, netilimicin updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI